Sogroya 10 MG/1.5ML 1 Pen contains a derivative of human growth hormone; it helps compensate for growth hormone deficiency and treat growth failure in children.
Sogroya injections contain the active ingredient somapacitan, a long-acting recombinant human growth hormone derivative. It works similarly to human growth hormone, which supports the growth of bones and muscles.
Sogroya is used for:
Treating growth hormone deficiency in children aged 3 years and older.
Adolescents with growth failure caused by growth hormone deficiency.
Adults with growth hormone deficiency.
The dose varies depending on age.
For children: doses start at 0.16 mg per kilogram of body weight per week.
For adults: doses range between 1.5 – 2 mg per week.
Sogroya is administered once weekly.
It is injected subcutaneously into the abdomen, thigh, or upper arm.
The injection site should be rotated each time.
Sogroya injections may cause some side effects, such as:
Headache.
Hypothyroidism.
Elevated blood sugar levels.
Joint pain.
Swelling of the extremities.
Fatigue.
Pain, swelling, or redness at the injection site.
Sogroya pen should not be used in cases of:
Hypersensitivity to its components.
Any evidence of active cancer.
Children with closed epiphyses (growth plates).
Severe illness, post-surgical complications, acute respiratory failure, or similar conditions.
Pregnancy.
Consult a doctor or pharmacist before using Sogroya alongside any other medication, especially:
Corticosteroids.
Oral estrogens.
Diabetes medications.
Thyroid hormones.
Epilepsy medications.
Keep out of reach of children.
Store in a refrigerator at 2 – 8°C.
Do not freeze.
If refrigeration is not possible, it may be stored at room temperature (up to 30°C) for a maximum of 72 hours.
Keep in its original packaging, protected from light.